Breast Cancer Research and Treatment **69:** 327, 2001.

Author index, Volume 69

Silliman, R.A., 81
Adam, A.P., 39
Aguggini, S., 143
Allevi, G., 143
Allison, J., 333
Alquati, P., 143
Andrykowski, M.A., 165
Berns, E.M.J.J., 65
Berruti, A., 143
Beryt, M., 53
Bisogna, M., 115
Bodini, M., 143
Bombardelli, E., 153
Bonanni, B., 21
Bottini, A., 143
Brizzi, M.P., 143
Brunelli, A., 143
Bydder, S., 65
Calvano, J.E., 115
Cantelmo, F., 153
Capafons, A., 1
Carpenter, J.S., 165
Cazzaniga, M., 21
Chang, J., 101
Coates, R.J., 133
Cohen, C., 81
Cordova, M.J., 165
Cunningham, L.L.C., 165
Decensi, A., 21
Dogliotti, L., 143
Elsaleh, H., 65
Kerner, J.F., 81
Felber, M., 53
Ferrandina, G., 153
Fink, V., 13
Fiorentino, C., 143
Frede, T., 13
Fritz, M., 53
Fruscella, E., 153
Gallo, D., 153
Gandini, S., 21
Giacomelli, S., 153
Gnanasampanthan, G., 65
Grieu, F., 65
Guerrieri-Gonzaga, A., 21
Hepp, H., 53
Ho, G.H., 115
Horwitz, K.B., 69
Horwitz, L.D., 69
Horwitz, M.A., 69
Hwang, Y.-T., 81
Iacopetta, B., 65
Lynch, J.J., 81
Joffé, E.B.D.K., 39
Johansson, H., 21
Kasimir-Bauer, S., 123
Kenady, D., 165
Konecny, G., 53
Ladeda, V., 39
Lebeau, A., 53
Lee, N.C., 133
Li, Z., 29
Lien, E.A., 21
Lin, H., 29
Lippman, M., 179
Lippman, M.E., 95
Lude, S., 53
Luo, J., 29
Elledge, R.M., 101
Mager, W., 165
Mancuso, S., 153
Marini, U., 143
Marth, C., 13
McGrath, P., 165
Mora, S., 21
Morazzoni, P., 153
Mueller-Holzner, E., 13
Neumann, R., 123
Oberhoff, C., 123
Olivetti, L., 143
Pahl, P.M.B., 69
Pegram, M., 53
Powell, B.L., 65
Puricelli, L., 39
Price, M.R., 1
Richardson, L.C., 133
Riva, A., 153
Robertson, C., 21
Mandelblatt, J.S., 81
Sandri, M.T., 21
Scambia, G., 153
Schindler, A.E., 123
Schulman, J., 133
Seeber, S., 123
Segal-Eiras, A., 1
Senie, R., 81
Seshadri, R., 65
Sever, L.E., 133
Slamon, D., 53
Sliwinska, K., 123
Sloan, D., 165
Studts, J.L., 165
Isla-Larrain, M.T., 1
Tira, A., 143
Torrisi, R., 21
Untch, M., 53
Croce, M.V., 1
Wang, M., 29
Zannoni, G.F., 153
Zee, K.J. V., 115
Zhu, Y., 29

Breast Cancer Research and Treatment **69:** 329–331, 2001.
© 2001 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 69

adherence
  after benign breast biopsy 165-178
adjuvant treated breast cancer
  TP53 gene modulation 65-68
alcohol
  correlation with breast cancer 29-38
anti-MUC1 antibodies
  in pregnant and healthy women 1-11
apoptosis
  induced by desferri-exochelin 69-79
  organ-specific modulation 39-51

benign breast biopsy
  adherence 165-178
biomarkers
  effect of tamoxifen 21-27
breast neoplasms
  effect of low dose tamoxifen 21-27

cancer registries
  for treatment among medically underserved women 133-142
chemoprevention
  effect on insulin-like growth factors 21-27
  use of tamoxifen 21-27
chemosensitivity
  effect of HER-2/neu overexpression 53-63
chemotherapy
  imaging techniques 143-151
  primary 143-151
  prognostic significance of *TP53* gene mutation 65-68
chemoprevention
  of chemically-induced mammary cancer 153-164
clinical follow-up
  after benign breast biopsy 165-178
clinical palpation
  response to primary chemotherapy 143-151
  versus imaging techniques 143-151
CMF
  HER-2/neu overexpression 53-63
  in vitro chemosensitivity 53-63
compliance
  to a clinical follow-up after benign breast biopsy 165-178
core biopsies
  determination of HER-2 expression 13-19
deferoxamine
  as an anti-cancer agent 69-79
  compared to desferri-exochelin 69-79
DEMO receptor
  in breast cells 101-113
desferri-exochelin
  killing breast cancer cells 69-79
differential display reverse transcription PCR
  modulation by ethanol 29-38

echography
  response to primary chemotherapy 143-151
  versus clinical palpation 143-151
EGF receptor
  in breast cells 101-113
elderly
  treated with mammography 81-91
E2F-1 expression
  in breast carcinoma 115-122
E2F-4 expression
  in breast carcinoma 115-122
ethanol
  correlation with breast cancer 29-38

FEC
  HER-2/neu overexpression 53-63
  in vitro chemosensitivity 53-63
  prognostic significance of *TP53* gene mutation 65-68

growth factors
  effect of tamoxifen 21-27

HER-2 expression
  in core biopsies and whole tumor specimens 13-19
  associated with poor prognosis 13-19
HER-2/neu
  chemosensitivity to CMF and FEC 53-63
  overexpression 53-63

transforming effect by ODC overexpression 101-113
hormonal therapy
prognostic significance of *TP53* gene mutation 65-68

ICI182780
resistance to killing by desferri-exochelin 69-79
imaging techniques
response to primary chemotherapy 143-151
immunohistochemistry
expression of HER-2 in core biopsies and whole tumor specimens 13-19
insulin-like growth factor system
effect of low dose tamoxifen 21-27
insurence
treatment among medically underserved women 133-142

lactation
relation with the level of MUC1 antibodies 1-11

mammary cancer
chemically-induced 153-164
in rats 153-164
soy activity 153-164
mammography treatment
in older women 81-91
response to primary chemotherapy 143-151
versus clinical palpation 143-151
MAPK signalling
role of HER-2/neu 101-113
MCF-7 cells
killed by desferri-exochelin 69-79
metastases
expression of E2F-1 115-122
expression of E2F-4 115-122
expression of ribosomal protein L7a 29-38
role of alcohol 29-38
microenvironment
of the lung 39-51
promotion of metastasis by organ-specific modulation 39-51
modulation of expression of ribosomal protein L7a
by ethanol 29-38
MUC1 antibodies
in pregnant and healthy women 1-11
MUC1-mucin
in pregnant and healthy women 1-11
mutation
role of E2F-1 and E2F-4 115-122

northern blot
promoting effect of ethanol on breast cancer 29-38

organ-specific modulation
of apoptosis 39-51

polyamides
involvement in cell proliferation 101-113
poor
and treatment options 133-142
predictive markers
HER-2 status of whole tumors 13-19
TP53 gene mutation 65-68
pregnant women
level of MUC1 antibodies 1-11
primary breast carcinoma
expression of E2F-1 and E2F-4 115-122
residual diseases 123-132
primary chemotherapy
accuracy of imaging techniques 143-151
prognostic markers
HER-2 overexpression 13-19
TP53 gene mutation 65-68
psychosocial factors
determining adherence for a clinical follow-up 165-178

rats
mammary cancer 153-164
soy activity 153-164
record linkages
comparing treatment among medically underserved women 133-142
residual diseases
detection in blood and bone marrow 123-132
in primary breast cancer 123-132
ribosomal protein L7a
modulation of expression 29-38
role of ethanol 29-38
R5020 cells
killed by desferri-exochelin 69-79

screening
comparing treatment among medically underserved women 133-142
selection for treatment
role of pretherapeutical HER-2 status 13-19
soy activity
in chemically-induced mammary cancer 153-164

stat signalling
role of HER-2/neu 101-113
stress response
affecting the expression of ribisomal protein L7a 29-38
survival factors
organ-specific modulation of apoptosis 39-51

tamoxifen
effect on the insulin-like growth factor system 21-27
low dose 21-27
TP53 gene mutation
in adjuvant treated breast cancer 65-68
transcriptional regulation
ribosomal protein L7a as a ethanol-responsive factor 29-38
trastuzumab
therapeutic benefit for patients with HER-2 overexpressing tumors 13-19
treatment options
for medically underserved women 133-142
for the elderly 81-91
for the poor 133-142
tumor cell dissemination
detection of residual diseases 123-132
tumor cell enrichment
detection of residual diseases 123-132
tumor differentiation
chemically-induced 153-164
in mammary cancer 153-164
in rats 153-164
tumor markers
residual diseases 123-132
T47D-YB cells
killed by desferri-exochelin 69-79

underinsurence
treatment among medically underserved women 133-142